ReviewCurrent molecular medicine2013
Antibody-based imaging of HER-2: moving into the clinic.
Review in Current molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Development and evaluation ofAsia Oceania journal of nuclear medicine & biology · 2023Article
- Progress in the Surface Functionalization of Selenium Nanoparticles and Their Potential Application in Cancer Therapy.Antioxidants (Basel, Switzerland) · 2022Review
- Fluorescent imaging for cancer therapy and cancer gene therapy.Molecular therapy oncolytics · 2021Review
- A Switchable Site-Specific Antibody Conjugate.ACS chemical biology · 2018Article
- Preclinical Development of CD38-Targeted [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- Alternative reagents to antibodies in imaging applications.Biophysical reviews · 2017Review
- CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies.PloS one · 2017Article
- Image-Guided Tumor Resection.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Human epidermal growth factor receptor-2 (HER-2) mediates a number of important cellular activities, and is up-regulated in a diverse set of cancer cell lines, especially breast cancer. Accordingly, HER-2 has been regarded as a common drug target in cancer therapy. Antibodies can serve as ideal candidates for targeted tumor imaging and drug delivery, due to their inherent affinity and specificity. Advanced by the development of a wide variety of imaging techniques, antibody-based imaging of HER-2 can allow for early detection and localization of tumors, as well as monitoring of drug delivery and tissue's response to drug treatment. In this review article, antibody-based imaging of HER-2 are summarized and discussed, with an emphasis on the involved imaging methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.